To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Axitinib
Axitinib (or AG013736) is produced by Pfizer and is a small molecule tyrosine kinase inhibitor. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in xenograft models [1] and has been successful in trials with renal cell carcinoma (RCC) [2] and several other tumor types [3]. References
|
||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Axitinib". A list of authors is available in Wikipedia. |